Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Gall (Giessen, Germany). Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. 3534

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Idiopathic pulmonary arterial hypertension in the elderly: Data from the French registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 TOPP: the first international registry in pediatric pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Interim analysis of pulmonary arterial hypertension (PAH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Incident pulmonary arterial hypertension in a Brazilian reference center: Results of a four-year registry Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Epidemiology of pulmonary hypertension: new data from the Swiss registry Source: Eur Respir J 2006; 28: Suppl. 50, 545s Year: 2006 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Pulmonary arterial hypertension prototype for national protocol and registry Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Clinical characteristics of pulmonary arterial hypertension in Ireland: results of a national register Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension Source: Eur Respir J 2015; 45: 1314-1322 Year: 2015 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016